This site is intended for health professionals only

Merck resubmits US application for Cladribine tablets

teaser

Merck KGaA announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for
Cladribine Tablets as a therapy for reducing relapses in people with relapsing forms of multiple sclerosis (MS).

The company received a refuse to file letter from the FDA for
the Cladribine Tablets NDA in November 2009.

Article continues below this sponsored advert
Advertisement

Regulatory filings for Cladribine Tablets are currently under review in a number of other locations including the European Union.

Merck






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x